Pharma and Biotech (DLS30)

 0.00
   
  • 52 Week High: NULL
  • 52 Week Low: 0.00

Sareum halts toxicology study after control-group safety findings

By Iain Gilbert

Date: Friday 10 Oct 2025

LONDON (ShareCast) - (Sharecast News) - Clinical-stage biotechnology firm Sareum said on Friday that it has discontinued its 16-week pre-clinical toxicology study for autoimmune and cancer candidate SDC-1801 after safety issues were flagged by a third-party provider.
The AIM-listed firm said dosing had been terminated and the study would be formally closed following final analysis. A preliminary review suggests the issues were "highly unlikely to be related to SDC-1801", with Sareum now working with consultants to determine next steps.

Sareum stated the findings were observed more frequently in control-group animals given an inactive solution than in those dosed with SDC-1801.

The study was intended to support longer-term dosing ahead of a planned Phase 2 trial in psoriasis, with Sareum now in talks with alternative providers to restart the study.

Sareum reiterated that its Phase 1 trial in healthy volunteers met all primary objectives, with no safety concerns identified and a pharmacokinetic profile consistent with once-daily dosing.

Executive chairman Dr Stephen Parker said: "While the need to terminate this study is frustrating, the preliminary data strongly suggest that the findings are unlikely to be associated with SDC-1801.

"Dosing has been terminated out of concern for animal welfare, and we are working closely with our partners and experts to understand the cause and identify a new provider with the aim of restarting the study as quickly as possible with our existing cash resources."

As of 0930 BST, Sareum shares had sunk 29.65% to 14p.





Reporting by Iain Gilbert at Sharecast.com

Email this article to a friend

or share it with one of these popular networks:


Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are end of day values only.

 

Price Data

Price 0.00
Closing Price Change 0.00
% Change 0.00 %
--25 Close 0.00

Top Risers

Price Change
VRCI 0.90p +16.1%
GNS 2,650.00p +4.1%
GUN 0.16p +3.2%
SCLP 10.00p +2.6%
PRTC 133.00p +1.8%
AVCT 71.00p +1.4%
POLB 3.60p +1.4%
HLN 342.10p +1.0%
OXB 647.00p +0.6%
GSK 1,627.50p +0.2%

Top Fallers

Price Change
FUM 2.00p -14.9%
NFX 0.23p -13.2%
PRM 1.87p -8.4%
GENF 2.00p -6.5%
SAR 14.50p -6.5%
IMM 10.40p -6.3%
APTA 0.99p -5.7%
AGY 8.00p -5.3%
OPTI 9.75p -4.9%
SVNS 0.36p -4.1%

Top of Page